MBT STAR®-BL RUO Assays

Selective Testing of Antibiotic Resistance caused by Beta-Lactamase

Hydrolysis of the ß-lactam ring of ß-lactam antibiotics

To aid the fight against resistant bacteria, Bruker has developed the MBT STAR^®-BL software module. This software expands the capabilities of the MALDI Biotyper^® beyond the identification of microorganisms by enabling fast and accurate analysis of the level of β-lactamase activity in bacterial cultures in microbiological research.

To analyze β-lactamase activity, bacteria samples are co-incubated with a β-lactam antibiotic. Bacteria with β-lactamase activity will be able to hydrolyze the antibiotic. This hydrolyzation is coupled with a mass shift of the molecule which can be measured using mass spectrometry.

After incubation, the co-incubation sample is spotted onto a MALDI target plate and spectra of the antibiotic are acquired. After spectra acquisition, the MBT STAR^®-BL software module automatically calculates the summed hydrolyzed and non-hydrolyzed (intact) antibiotic signal intensities and the corresponding ratio. Results are displayed as a plot that enables at-a-glance evaluation.

The assays can conveniently be performed within approximately one hour by utilizing the easy to use MBT STAR^®-Carba and MBT STAR^®-Cepha Kits, for rapid detection of carbapenemase and cephalosporinase activity respectively, starting from a culture plate or Sepsityper pellet.

For Research Use Only. Not for use in clinical diagnostic procedures.

Please contact your local representative for availability in your country.